01:11 PM EST, 12/11/2024 (MT Newswires) -- Scilex Holding's ( SCLX ) Scilex Bio venture with IPMC said Wednesday it is enrolling patients with Alzheimer's disease showing mild cognitive impairment and mild dementia in the phase 2 study of KDS2010.

The company is currently enrolling 114 subjects in South Korea and enrollment of the US cohort will begin in 2025, Scilex Bio said.

Scilex Bio said it will evaluate the safety and efficacy of the drug in the randomized, double-blind, placebo-controlled study.

IPMC is a representative company of the Bio Innovation Consortium, which holds exclusive rights to NeuroBiogen's KDS2010 global license.

Price: 0.56, Change: -0.01, Percent Change: -2.59